PROSPECTIVE STUDY OF ASPIRIN FOR THROMBOEMBOLISM PROPHYLAXIS IN TOTAL HIP ARTHROPLASTY

Autor: RAUL CARNEIRO LINS, EPITÁCIO LEITE ROLIM FILHO, FERNANDO DE SANTA CRUZ OLIVEIRA, SAULO MONTEIRO DOS SANTOS, TALE LUCAS VIEIRA ROLIM, FLÁVIO KREIMER

Publikováno v: Acta Ortopédica Brasileira, Vol 26, Iss 2, Pp 86-90 (2018)

ABSTRACT Objectives: To evaluate the effectiveness of aspirin as prophylaxis for deep venous thrombosis (DVT) in patients undergoing total hip arthroplasty (THA), and to analyze the incidence of bleeding during the post-operative period. Methods: Thi

Externí odkaz: https://doaj.org/article/ad7507ef8cad448eb4de721ee51793cb

Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury

Autor: R J, Eck, J J C M, van de Leur, R, Wiersema, E G M, Cox, W, Bult, A J, Spanjersberg, I C C, van der Horst, M V, Lukens, R O B, Gans, K, Meijer, F, Keus

Publikováno v: Scientific Reports, 12(1). Nature Publishing Group
Scientific Reports, 12(1):17408. Nature Publishing Group

Our objective was to assess the incidence of drug bioaccumulation in critically ill COVID-19 patients with AKI receiving intermediate dose nadroparin for thrombosis prophylaxis. We conducted a Prospective cohort study of critically ill COVID-19 patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9efcbe6add63ba023e15ad37a16eee0d
https://research.rug.nl/en/publications/199299d0-7e75-4305-98dd-1951dfab50e4

How to optimize the prevention of post-thrombotic syndrome: recent advances

Autor: Aaron F.J. Iding, Arina J. ten Cate-Hoek

Publikováno v: Polish Archives of Internal Medicine.

Post‑thrombotic syndrome (PTS) is the most frequent complication of deep vein thrombosis, and it can be detrimental to the quality of life of the affected patients. Once affected by this chronic condition, the patient's treatment options are very l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2570f06eb546a3811cb3c02a4c370588
https://doi.org/10.20452/pamw.16288

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Autor: Goligher, Ewan C, Bradbury, Charlotte A, McVerry, Bryan J, Lawler, Patrick R, Berger, Jeffrey S, Gong, Michelle N, Carrier, Marc, Reynolds, Harmony R, Kumar, Anand, Turgeon, Alexis F, Kornblith, Lucy Z, Kahn, Susan R, Marshall, John C, Kim, Keri S, Houston, Brett L, Derde, Lennie PG, Cushman, Mary, Tritschler, Tobias, Angus, Derek C, Godoy, Lucas C, McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E, Brooks, Maria M, Lewis, Roger J, Berry, Lindsay R, Lorenzi, Elizabeth, Gordon, Anthony C, Berry, Scott M, McArthur, Colin J, Neal, Matthew D, Hochman, Judith S, Webb, Steven A, Zarychanski, Ryan, Ahuja, Tania, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Kreuziger, Lisa Baumann, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Contreras, Aira, Costantini, Todd W, de Brouwer, Sophie, Detry, Michelle A, Duggal, Abhijit, Dzavik, Vladimir, Effron, Mark B, Eng, Heather F, Escobedo, Jorge, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Froess, Joshua D, Fu, Zhuxuan, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, Girard, Timothy D, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Haniffa, Rashan, Hegde, Sheila M, Hendrickson, Carolyn M, Higgins, Alisa M, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Huang, David T, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei, King, Andrew J, Kornblith, Aaron E, Kutcher, Matthew E, Laffan, Michael A, Lamontagne, Francois, Le Gal, Gregoire, Leeper, Christine M, Leifer, Eric S, Lim, George, Lima, Felipe Gallego, Linstrum, Kelsey, Litton, Edward, Lopez-Sendon, Jose, Lother, Sylvain A, Marten, Nicole, Marinez, Andrea Saud, Martinez, Mary, Garcia, Eduardo Mateos, Mavromichalis, Stavroula, McAuley, Daniel F, McDonald, Emily G, McGlothlin, Anna, McGuinness, Shay P, Middeldorp, Saskia, Montgomery, Stephanie K, Mouncey, Paul R, Murthy, Srinivas, Nair, Girish B, Nair, Rahul, Nichol, Alistair D, Nicolau, Jose C, Nunez-Garcia, Brenda, Park, John J, Park, Pauline K, Parke, Rachael L, Parker, Jane C, Parnia, Sam, Paul, Jonathan D, Pompilio, Mauricio, Quigley, John G, Rosenson, Robert S, Rost, Natalia S, Rowan, Kathryn, Santos, Fernanda O, Santos, Marlene, Santos, Mayler O, Satterwhite, Lewis, Saunders, Christina T, Schreiber, Jake, Schutgens, Roger EG, Seymour, Christopher W, Siegal, Deborah M, Silva, Delcio G, Singhal, Aneesh B, Slutsky, Arthur S, Solvason, Dayna, Turner, Anne M, Van Bentum-Puijk, Wilma, van de Veerdonk, Frank L, van Diepen, Sean, Vazquez-Grande, Gloria, Wahid, Lana, Wareham, Vanessa, Widmer, R Jay, Wilson, Jennifer G, Yuriditsky, Eugene, Zhong, Yongqi, Investigators, REMAP-CAP, Investigators, ACTIV-4a, Investigators, ATTACC

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 385 (9), pp.777-789. ⟨10.1056/NEJMoa2103417⟩
New England journal of medicine, 385(9), 777-789. Massachussetts Medical Society
et al. 2021, ' Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 ', New England Journal of Medicine, vol. 385, no. 9, pp. 777-789 . https://doi.org/10.1056/NEJMoa2103417
NEW ENGLAND JOURNAL OF MEDICINE
The New England Journal of Medicine, 385, 9, pp. 777-789
Investigators, REMAP-CAP & Dark, P 2021, ' Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 ', The New England Journal of Medicine, vol. 385, no. 9, pp. 777-789 . https://doi.org/10.1056/NEJMoa2103417
The New England Journal of Medicine, 385, 777-789
The New England journal of medicine

BACKGROUNDThrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85dfa0ff9303f71a226cade0fe2e7521
https://doi.org/10.1056/nejmoa2103417

A Genotype-Guided Strategy for Oral P2Y(12) Inhibitors in Primary PCI

Autor: Claassens, Daniel M F, Vos, Gerrit J A, Bergmeijer, Thomas O, Hermanides, Renicus S, van 't Hof, Arnoud W J, van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M, Asselbergs, Folkert W, Mosterd, Arend, Herrman, Jean-Paul R, Dewilde, Willem J M, Janssen, Paul W A, Kelder, Johannes C, Postma, Maarten J, de Boer, Anthonius, Boersma, Cornelis, Deneer, Vera H M, Ten Berg, Jurriën M, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology

Publikováno v: New England Journal of Medicine, 381(17), 1621-1631. MASSACHUSETTS MEDICAL SOCIETY
New England Journal of Medicine, 381(17), 1621-1631. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine, 381, 1621. Massachussetts Medical Society
New England Journal of Medicine, 381(17), 1621. Massachussetts Medical Society

BackgroundIt is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y(12) inhibitors.MethodsWe conducted a randomized, open-label, assessor-blinded trial in which patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::733c98faebcd29c4b96c53bc67fcb7de
https://hdl.handle.net/11370/650391a9-784b-433f-a595-a7bf8062502a